Medicure Inc. (OTCMKTS:MCUJF) Sees Large Increase in Short Interest

Medicure Inc. (OTCMKTS:MCUJF) was the recipient of a large growth in short interest in the month of October. As of October 30th, there was short interest totaling 16,610 shares, a growth of 396.1% from the October 15th total of 3,348 shares. Based on an average daily volume of 29,975 shares, the short-interest ratio is currently 0.6 days. Approximately 0.2% of the shares of the company are sold short.

Medicure Price Performance

Shares of MCUJF remained flat at $2.60 on Thursday. 16,640 shares of the company were exchanged, compared to its average volume of 12,721. The company has a quick ratio of 0.64, a current ratio of 0.97 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $27.30 million, a PE ratio of -5.10 and a beta of 1.10. The company’s 50-day moving average price is $2.38 and its 200 day moving average price is $1.23. Medicure has a one year low of $0.67 and a one year high of $3.45.

Medicure (OTCMKTS:MCUJF) last announced its earnings results on Friday, August 14th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.05). Medicure had a negative net margin of 23.14% and a negative return on equity of 54.55%. The business had revenue of $5.36 million for the quarter, compared to the consensus estimate of $2.45 million.

Medicure Company Profile

Medicure Inc. is a Canadian pharmaceutical company focused on developing and commercializing therapies for cardiovascular and related serious medical conditions. The company is headquartered in Winnipeg, Manitoba, and serves healthcare markets primarily through its U.S. pharmaceutical operations. Medicure’s principal commercial product is AGGRASTAT (tirofiban hydrochloride), an intravenous antiplatelet medication used to help reduce thrombotic cardiovascular events in patients with acute coronary syndromes, including non-ST-segment elevation acute coronary syndrome.